FDA 483 - Noble Pharma, LLC - August 22, 2025

Noble Pharma, LLC, a pharmaceutical manufacturer, was cited for significant deficiencies in its quality system. The inspection revealed a failure to record and investigate deviations from written production and process control procedures, including issues noted in batch records and an instrument malfunction. This indicates a lack of adequate control over manufacturing processes and laboratory operations.